546 related articles for article (PubMed ID: 30248941)
21. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies.
Medina MA; Oza G; Sharma A; Arriaga LG; Hernández Hernández JM; Rotello VM; Ramirez JT
Int J Environ Res Public Health; 2020 Mar; 17(6):. PubMed ID: 32245065
[TBL] [Abstract][Full Text] [Related]
22. Triple-negative breast cancer: understanding Wnt signaling in drug resistance.
Merikhian P; Eisavand MR; Farahmand L
Cancer Cell Int; 2021 Aug; 21(1):419. PubMed ID: 34376211
[TBL] [Abstract][Full Text] [Related]
23. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
24. The anticancer mechanism of action of selected polyphenols in triple-negative breast cancer (TNBC).
Farghadani R; Naidu R
Biomed Pharmacother; 2023 Sep; 165():115170. PubMed ID: 37481930
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
26. Natural Plants Compounds as Modulators of Epithelial-to-Mesenchymal Transition.
Avila-Carrasco L; Majano P; Sánchez-Toméro JA; Selgas R; López-Cabrera M; Aguilera A; González Mateo G
Front Pharmacol; 2019; 10():715. PubMed ID: 31417401
[TBL] [Abstract][Full Text] [Related]
27. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
28. Altersolanol B, a fungal tetrahydroanthraquinone, inhibits the proliferation of estrogen receptor-expressing (ER+) human breast adenocarcinoma by modulating PI3K/AKT, p38/ERK MAPK and associated signaling pathways.
Siraj MA; Jacobs AT; Tan GT
Chem Biol Interact; 2022 May; 359():109916. PubMed ID: 35346647
[TBL] [Abstract][Full Text] [Related]
29. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
30. Curcumin and quercetin synergistically inhibit cancer cell proliferation in multiple cancer cells and modulate Wnt/β-catenin signaling and apoptotic pathways in A375 cells.
Srivastava NS; Srivastava RAK
Phytomedicine; 2019 Jan; 52():117-128. PubMed ID: 30599890
[TBL] [Abstract][Full Text] [Related]
31. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
32. Targeting triple negative breast cancer heterogeneity with chalcones: a molecular insight.
Elkhalifa D; Alali F; Al Moustafa AE; Khalil A
J Drug Target; 2019 Sep; 27(8):830-838. PubMed ID: 30582377
[TBL] [Abstract][Full Text] [Related]
33. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Huang O; Zhang W; Zhi Q; Xue X; Liu H; Shen D; Geng M; Xie Z; Jiang M
Exp Biol Med (Maywood); 2015 Apr; 240(4):426-37. PubMed ID: 25304315
[TBL] [Abstract][Full Text] [Related]
34. Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer.
Farghadani R; Naidu R
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298639
[TBL] [Abstract][Full Text] [Related]
35. Curcumin prevented human autocrine growth hormone (GH) signaling mediated NF-κB activation and miR-183-96-182 cluster stimulated epithelial mesenchymal transition in T47D breast cancer cells.
Coker-Gurkan A; Bulut D; Genc R; Arisan ED; Obakan-Yerlikaya P; Palavan-Unsal N
Mol Biol Rep; 2019 Feb; 46(1):355-369. PubMed ID: 30467667
[TBL] [Abstract][Full Text] [Related]
36. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
37. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins.
Merlin JL; Harlé A; Lion M; Ramacci C; Leroux A
Oncol Rep; 2013 Oct; 30(4):1943-8. PubMed ID: 23900300
[TBL] [Abstract][Full Text] [Related]
38. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
Yam C; Mani SA; Moulder SL
Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
[TBL] [Abstract][Full Text] [Related]
39. Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met.
Ebrahim HY; Elsayed HE; Mohyeldin MM; Akl MR; Bhattacharjee J; Egbert S; El Sayed KA
Phytother Res; 2016 Apr; 30(4):557-66. PubMed ID: 26744260
[TBL] [Abstract][Full Text] [Related]
40. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.
Reddy D; Kumavath R; Tan TZ; Ampasala DR; Kumar AP
Life Sci; 2020 Jan; 241():117147. PubMed ID: 31830480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
